• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌患者长期低剂量治疗后环磷酰胺的药代动力学

Pharmacokinetics of cyclophosphamide after prolonged low dose treatment in ovarian cancer patients.

作者信息

D'Incalci M, Facchinetti T, Bolis G, Mangioni C, Morasca L

出版信息

Eur J Drug Metab Pharmacokinet. 1979;4(2):83-5. doi: 10.1007/BF03189405.

DOI:10.1007/BF03189405
PMID:114397
Abstract

We have studied Cyclophosphamide (Cy) pharmacokinetics in 9 patients after their first intravenous dose of 100 mg, and in 9 patients after 6--13 months of continual treatment with the same dose every day. The half-life of Cy was shorter (p less than 0.05) in the latter group, the Co was greater (less than 0.01) and the Vd was clearly less (p less than 0.01). The AUC was unchanged.

摘要

我们研究了9例患者首次静脉注射100毫克环磷酰胺(Cy)后的药代动力学,以及9例患者每天使用相同剂量持续治疗6至13个月后的药代动力学。Cy的半衰期在后一组中较短(p<0.05),血药浓度-时间曲线下面积(Co)较高(<0.01),而分布容积(Vd)明显较小(p<0.01)。曲线下面积(AUC)未发生变化。

相似文献

1
Pharmacokinetics of cyclophosphamide after prolonged low dose treatment in ovarian cancer patients.卵巢癌患者长期低剂量治疗后环磷酰胺的药代动力学
Eur J Drug Metab Pharmacokinet. 1979;4(2):83-5. doi: 10.1007/BF03189405.
2
Decreased half life of cyclophosphamide in patients under continual treatment.持续治疗患者中,环磷酰胺的半衰期缩短。
Eur J Cancer (1965). 1979 Jan;15(1):7-10. doi: 10.1016/0014-2964(79)90198-1.
3
Decreased plasma half-life of cyclophosphamide during repeated high-dose administration.
Cancer Chemother Pharmacol. 1983;10(3):192-3. doi: 10.1007/BF00255760.
4
Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients.人骨髓移植患者中,环磷酰胺和羟基环磷酰胺的处置与预处理方案有关。
J Clin Oncol. 1996 May;14(5):1484-94. doi: 10.1200/JCO.1996.14.5.1484.
5
Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer.在乳腺癌和卵巢癌患者中给予紫杉醇、环磷酰胺和非格司亭后采集外周血干细胞。
Biol Blood Marrow Transplant. 1997 Jun;3(2):83-90.
6
A bioassay for cyclophosphamide in blood, lung and tumour.血液、肺和肿瘤中环磷酰胺的生物测定法。
Br J Cancer. 1984 Jan;49(1):49-55. doi: 10.1038/bjc.1984.8.
7
Treatment of advanced ovarian carcinoma with high-dose cyclophosphamide after falure on melphalan.在美法仑治疗失败后,用大剂量环磷酰胺治疗晚期卵巢癌。
Cancer Treat Rep. 1977 Oct;61(7):1369-71.
8
Pharmacokinetics of the cytostatic drugs used in the CMF-regimen.CMF方案中使用的细胞毒性药物的药代动力学。
Anticancer Res. 1983 Jul-Aug;3(4):269-71.
9
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.环磷酰胺用于治疗晚期卵巢癌时对卡铂暴露与反应或毒性之间关系的影响。
J Clin Oncol. 1993 Jun;11(6):1156-64. doi: 10.1200/JCO.1993.11.6.1156.
10
Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.静脉注射和口服后环磷酰胺在人体中的药代动力学及烷化活性
Br J Clin Pharmacol. 1979 Sep;8(3):209-17. doi: 10.1111/j.1365-2125.1979.tb01004.x.

引用本文的文献

1
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.贝伐珠单抗、索拉非尼和低剂量环磷酰胺治疗儿童和青年难治/复发性实体瘤的 I 期和临床药理学研究。
Clin Cancer Res. 2013 Jan 1;19(1):236-46. doi: 10.1158/1078-0432.CCR-12-1897. Epub 2012 Nov 8.

本文引用的文献

1
[ON THE ACTIVATION OF CYCLOPHOSPHAMIDE IN VIVO AND IN VITRO].[关于环磷酰胺在体内和体外的活化作用]
Arzneimittelforschung. 1963 Dec;13:1021-31.
2
Studies on the mechanism of action of cytoxan. Evidence of activation in vivo and in vitro.环磷酰胺作用机制的研究。体内和体外激活的证据。
Cancer Res. 1961 Jan;21:57-63.
3
Drug metabolism after repeated treatments with cytotoxic agents.细胞毒性药物重复治疗后的药物代谢。
Eur J Cancer (1965). 1971 Aug;7(4):361-4. doi: 10.1016/0014-2964(71)90081-8.
4
Pharmacokinetics of cyclophosphamide in man.环磷酰胺在人体中的药代动力学。
Br J Pharmacol. 1971 Nov;43(3):677-80. doi: 10.1111/j.1476-5381.1971.tb07199.x.
5
Enzymatic metabolism of cyclophosphamide and nicotine and production of a toxic cyclophosphamide metabolite.
Cancer Res. 1972 Apr;32(4):658-65.
6
Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.一些关于环磷酰胺和异环磷酰胺微粒体代谢过程中形成的活性中间体的研究。
Biochem Pharmacol. 1974 Jan 1;23(1):115-29. doi: 10.1016/0006-2952(74)90318-9.
7
The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.环磷酰胺在人体内的生物转化:正常受试者的变异分析。
Acta Pharmacol Toxicol (Copenh). 1974 Aug;35(2):98-106. doi: 10.1111/j.1600-0773.1974.tb00729.x.
8
Metabolism of cyclophosphamide by rat hepatic microsomes.大鼠肝微粒体对环磷酰胺的代谢
Cancer Res. 1971 Jun;31(6):901-8.
9
Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat.大鼠肝脏微粒体对环磷酰胺激活作用的酶学基础。
J Pharmacol Exp Ther. 1970 Aug;174(2):206-10.
10
Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.环磷酰胺(NSC - 26271)、环磷酰胺代谢物与普通氮芥化合物的体内外比较药理学研究。
Cancer Treat Rep. 1976 Apr;60(4):301-8.